Bonedol (0.25ug) 10 Tablets

Alfacalcidol, the active ingredient in the 0.25 microgram tablet, is a synthetic analog of vitamin D. Its mechanism of action primarily involves mimicking the effects of naturally occurring vitamin D metabolites in the body. Alfacalcidol is metabolized in the liver to form 1,25-dihydroxyvitamin D, the active form of vitamin D. This active metabolite binds to vitamin D receptors (VDRs) in various target tissues, primarily in the intestine, kidneys, and bones. By activating VDRs, alfacalcidol promotes the absorption of calcium and phosphate from the intestines, increases renal tubular reabsorption of calcium, and mobilizes calcium and phosphate from bone. These actions collectively contribute to the maintenance of calcium and phosphate homeostasis, promoting bone mineralization and preventing hypocalcemic conditions. Alfacalcidol's mechanism of action makes it useful in the treatment of various conditions related to calcium and vitamin D metabolism disorders.

Alfacalcidol 0.25ug

Vitamin D analogue.

Tablet

The following are the uses of Alfacalcidol 0.25ug Tablet:

• Used for treating and preventing low levels of calcium in the blood, often caused by kidney or parathyroid issues.
• Used for managing conditions like rickets, osteomalacia, and osteoporosis, where bone strength and development are compromised.
• Used for correcting calcium and phosphate imbalances in patients with chronic kidney disease.
• Used for alleviating symptoms related to calcium deficiency, such as bone pain and muscle weakness.
• Used for supporting bone health and mineralization, especially in individuals with impaired vitamin D metabolism.
• Used for regulating calcium and phosphate metabolism in patients with malabsorption syndromes.
• Used for maintaining calcium homeostasis during specific medical treatments or surgeries.

Tailoring Treatment for Optimal Health, Prescribed Medication Dosage is:

• For adults taking immunosuppressants for mild to moderate hypophosphatemia- Start with 1 tablet of Alfacalcidol 0.5μg per day.
• For treating vitamin D dependent rickets and kidney hemodialysis- Start with 1-2 tablets of Alfacalcidol 0.5μg per day.
• For children- Doses are based on weight and medical condition, so follow the doctor's instructions.

In the case of an overdose of Alfacalcidol 0.25ug Tablets, it is important to recognize the potential symptoms. These may include nausea, vomiting, muscle weakness, and an increase in calcium levels. Promptly seek medical advice if you suspect an overdose, as treatment may involve supportive care and managing calcium levels to prevent further complications. Early intervention is key to minimizing the impact of an overdose.

In the case of a missed dose of Alfacalcidol 0.25ug Tablet, it is generally recommended to take the missed dose as soon as you remember. However, if it's almost time for your next scheduled dose, it's best to skip the missed dose and continue with your regular dosing schedule. Avoid taking a double dose to make up for a missed one. If you've missed multiple doses, consult your healthcare provider for guidance on how to safely adjust your medication routine and get back on track.

To take Alfacalcidol 0.25ug Tablet, place the tablet under your tongue and allow it to dissolve completely without chewing or swallowing, preferably on an empty stomach, following the dosage instructions provided by your healthcare professional.

Following are the conditions or situations when Alfacalcidol 0.25ug Tablet should not be taken:

• Should not be used in individuals with hypercalcemia (high levels of calcium in the blood).
• Contraindicated in patients with hypercalciuria (high levels of calcium in urine) and calcium-containing kidney stones.
• Not suitable for individuals with known hypersensitivity or allergy to Alfacalcidol or any of its components.
• Should be avoided in patients with severe renal impairment or end-stage kidney disease.
• Should not be used in individuals with uncontrolled vitamin D toxicity.
• Contraindicated during pregnancy, especially in the first trimester, unless clearly necessary.
• Not recommended for individuals with severe cardiovascular diseases, as it may increase the risk of calcification in blood vessels.
• Should be used with caution and under medical supervision in people with hyperparathyroidism.

The side effects of Alfacalcidol 0.25µg Tablet may include:

• Nausea and vomiting.
• Constipation or diarrhea.
• Loss of appetite.
• Increased thirst and frequent urination.
• Muscle weakness or bone pain.
• Headache and dizziness.
• Itching or skin rash.
• Elevated calcium levels in the blood (hypercalcemia), which may lead to fatigue, confusion, and kidney problems.

Following are the precautions and warnings for Alfacalcidol 0.25ug Tablet:

• This medication should be used with caution in patients with kidney disease, as it may require dosage adjustments under medical supervision.
• Regular monitoring of calcium and phosphate levels in the blood is essential during treatment.
• Patients with a history of allergic reactions to vitamin D or related compounds should avoid Alfacalcidol.
• Not recommended for individuals with high calcium or low phosphate levels in the blood.
• Elderly patients may be more susceptible to the effects of Alfacalcidol, and close monitoring is necessary.
• Avoid consuming calcium supplements or calcium-rich antacids without medical advice while on this medication.
• Alfacalcidol may interact with other medications; inform your doctor about all the medicines you are taking to prevent adverse reactions.

Following are the drug interactions for Alfacalcidol 0.5ug Tablet:

• Anticonvulsants like phenytoin or carbamazepine may decrease the effectiveness of Alfacalcidol.
• Thiazide diuretics can enhance the effects of Alfacalcidol, requiring careful monitoring.
• Calcium-containing antacids may reduce Alfacalcidol absorption when taken simultaneously.
• Corticosteroids such as prednisone can increase calcium excretion, requiring dose adjustments.
• Taking digoxin with Alfacalcidol may lead to elevated calcium levels, necessitating close monitoring.
• Mineral oil laxatives can interfere with Alfacalcidol absorption, so separate administration is advised.
• Certain antibiotics like tetracyclines may have reduced absorption when taken with Alfacalcidol.

Following are the food interactions for Alfacalcidol 0.25ug Tablet:

• Alfacalcidol may interact with calcium-rich foods like milk, cheese, and yogurt, as well as calcium supplements. These can affect the absorption and effectiveness of the medication.
• Avoid excessive consumption of foods rich in vitamin D, such as fatty fish, egg yolks, and fortified dairy products, as it may lead to vitamin D toxicity.
• Grapefruit and grapefruit juice should be limited as they can interfere with the metabolism of Alfacalcidol, potentially raising its levels in the blood.
• Alcohol can increase the risk of kidney damage when used with Alfacalcidol, so it's best to limit or avoid alcohol consumption.
• Avoid high-phosphorus foods like red meat, organ meats, and carbonated beverages, as phosphorus can affect calcium and vitamin D metabolism.
• Leafy green vegetables like spinach and kale contain oxalates, which can bind with calcium and reduce its absorption, potentially affecting the medication's effectiveness.
• Salt substitutes containing potassium chloride should be used cautiously, as they can affect the balance of electrolytes in the body.

Alfacalcidol 0.25ug Tablets should be stored in a cool and dry place, preferably at room temperature, ensuring it remains protected from direct sunlight and moisture. The medication should be kept in its original container, tightly sealed, to maintain its integrity and prevent contamination. It is crucial not to expose the tablets to extreme temperatures, so avoid storing them near heat sources. Always check the expiration date before use, and never use expired medication. For proper disposal, do not flush or pour the tablets down the drain; instead, seek guidance from a pharmacist or healthcare professional on the appropriate disposal methods to ensure environmental safety. Keep the medication securely stored, out of the reach of children, to prevent accidental consumption.

Following are the quick tips for Alfacalcidol 0.25ug Tablet:

• Consult your doctor for the right dosage and duration based on your medical condition.
• Take the tablet orally, preferably with or after a meal, to enhance absorption.
• Swallow the tablet whole without crushing or chewing for optimal effects.
• Maintain a consistent schedule for taking the medication as directed.
• Do not miss doses; if you forget, take it as soon as you remember, unless it's almost time for the next dose.
• Inform your doctor about all medications you are currently taking to avoid drug interactions.
• Store the tablets in a cool, dry place, away from direct sunlight and moisture.

Alfacalcidol is a vitamin D derivative that acts as a therapeutic agent for conditions like hypocalcemia and metabolic bone disease among individuals who have kidney failure. The laboratory tests required to accompany Alfacalcidol depend on the individual's medical situation and the condition that is being treated. In general, it is important to monitor vitamin D levels, calcium, and phosphate levels in the blood to ensure they are within the normal range. Given the nature of the medication and its potential impact on the kidneys, kidney function tests are often required, checking for example for BUN (blood urea nitrogen) and creatinine. It is also important to monitor for any potential adverse effects of the medication on kidney function. Other relevant tests may include parathyroid hormone levels and osteocalcin, as well as regular assessments of calcium homeostasis to ensure that the treatment is effective and to avoid the development of hypercalcemia which can lead to serious complications. It is vital to adhere to any testing schedules outlined by your healthcare provider when taking Alfacalcidol to ensure effective use and to monitor for any potential side effects or unintended consequences. The specific testing regime and timing of the tests would be advised by the prescribing physician who can tailor the monitoring to the individual based on their clinical condition and response to the medication.